acute myeloid leukemia (AML) | Aplastic Anemia and MDS International Foundation

acute myeloid leukemia (AML)

Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome

Author(s): 
Slade M, DiPersio J, Westervelt P, Vij R, Schroeder M, Romee R
Primary Author: 
Slade M
Journal Title: 
Biology of Blood and Marrow Transplantation
Original Publication Date: 
Nov 2017

Many hematologic malignancies are diseases of aging, and the use of hematopoietic cell transplant (HCT) is growing rapidly among older adults. Modern post-transplant

Orlando

Thank you for attending the 2017 Patient and Family Conference in Orlando, FL.

Thank you for attending the 2017 Patient and Family Conference in Orlando, FL.
Event Date: 
Sat, 11/04/2017 -
8:00am to 3:30pm
Conference Event Type: 

Kansas City

Thank you for attending the 2017 Patient and Family Conference in Kansas City, MO.

Thank you for attending the 2017 Patient and Family Conference in Kansas City, MO.
Event Date: 
Sat, 10/14/2017 -
7:30am to 1:30pm
Conference Event Type: 

Gemtuzumab Receives New FDA Approval for Acute Myeloid Leukemia

Author(s): 
NCI Staff
Primary Author: 
NCI Staff
Journal Title: 
NIHNCI
Original Publication Date: 
Sep 2017

On September 1, the Food and Drug Administration (FDA) approved gemtuzumab ozogamicin (Mylotarg™) for some patients with acute myeloid leukemia (AML).

The approval covers the use of gemtuzumab in adults with newly diagnosed AML that expresses a protein called CD33 (CD33-positive AML). The approval also covers the treatment of patients aged 2 and older with CD33-positive AML who have experienced a relapse or whose disease has not responded to initial treatment.

Bone Marrow Diseases: 

Clinical trial reveals genetic fault that reduces the effectiveness of leukemia treatment

Author(s): 
University of Birmingham
Primary Author: 
University of Birmingham
Journal Title: 
Science Codex
Original Publication Date: 
Sep 2017

A genetic fault has been identified in people with an aggressive type of leukaemia that can significantly affect how they respond to treatment.

Newark

Thank you for attending the 2017 Patient and Family Conference in Newark, NJ.

Thank you for attending the 2017 Patient and Family Conference in Newark, NJ.
Event Date: 
Sat, 09/16/2017 -
8:00am to 3:30pm
Conference Event Type: 

Minneapolis

Thank you for attending the 2017 Minneapolis Patient and Family Conference.

Event Date: 
Sat, 07/22/2017 -
8:00am to 3:30pm
Conference Event Type: 

Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia

Author(s): 
Eytan M. Stein, Courtney D. DiNardo, Daniel A. Pollyea, Amir T. Fathi, Gail J. Roboz, Jessica K. Altman, Richard M. Stone, Daniel J. DeAngelo, Ross L. Levine, Ian W. Flinn, Hagop M. Kantarjian, Robert Collins, Manish R. Patel, Arthur E. Frankel, Anthony S
Primary Author: 
Eytan M. Stein
Journal Title: 
Blood
Original Publication Date: 
May 2017

Recurrent mutations in isocitrate dehydrogenase 2 (IDH2) occur in ~12% of patients with acute myeloid leukemia (AML). Mutated IDH2 proteins neomorphically synthesize 2-hydroxyglutarate resulting in DNA and histone hypermethylation, leading to blocked cellular differentiation. Enasidenib (AG-221/CC-90007) is a first-in-class, oral, selective inhibitor of mutant-IDH2 enzymes.

Bone Marrow Diseases: 

Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents

Author(s): 
Park S, Hamel JF, Toma A, Kelaidi C, Thépot S, Campelo MD, Santini V, Sekeres MA, Balleari E, Kaivers J, Sapena R, Götze K, Müller-Thomas C, Beyne-Rauzy O, Stamatoullas A, Kotsianidis I, Komrokji R, Steensma DP, Fensterl J, Roboz GJ, Bernal T, Ramos F
Primary Author: 
Park S
Journal Title: 
J Clin Oncol
Original Publication Date: 
Mar 2017

Purpose Most anemic patients with non-deleted 5q lower-risk

Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1

Author(s): 
Jurjen Versluis, Myriam Labopin, Annalisa Ruggeri, Gerard Socie, Depei Wu, Liisa Volin, Didier Blaise, Noel Milpied, Charles Craddock, Ibrahim Yakoub-Agha, Johan Maertens, Per Ljungman, Anne Huynh, Mauricette Michallet, Eric Deconinck, Patrice Chevallier
Primary Author: 
Jurjen Versluis
Journal Title: 
Blood Advances
Original Publication Date: 
Mar 2017

Allogeneic hematopoietic stem cell transplantation (alloHSCT) remains the treatment of choice to consolidate remission in patients with poor-risk acute myeloid leukemia (AML). With increasing alternative donors available, the preferred donor or stem cell source is debated. We set out to study outcome in recipients of alloHSCT with poor-risk AML in first complete remission (CR1) by donor type.

Bone Marrow Diseases: